259 related articles for article (PubMed ID: 33280246)
1. The critical impact of tumor size in predicting cancer special survival for T3aM0M0 renal cell carcinoma: A proposal of an alternative T3aN0M0 stage.
Li L; Shi L; Zhang J; Fan Y; Li Q
Cancer Med; 2021 Jan; 10(2):605-614. PubMed ID: 33280246
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0/xM0: Survival benefit is biased toward partial nephrectomy.
Liu S; Feng C; Liu C; Wang Z
Cancer Med; 2021 Dec; 10(24):8909-8923. PubMed ID: 34779154
[TBL] [Abstract][Full Text] [Related]
3. Local ablation vs partial nephrectomy in T1N0M0 renal cell carcinoma: An inverse probability of treatment weighting analysis.
Shi L; He Y; Liu C; Qian X; Wang Z
Cancer Med; 2020 Nov; 9(21):7988-8003. PubMed ID: 32888392
[TBL] [Abstract][Full Text] [Related]
4. Does stage T3a renal cell carcinoma embrace a homogeneous group of patients?
Gofrit ON; Shapiro A; Pizov G; Landau EH; Katz R; Zorn KC; Pode D
J Urol; 2007 May; 177(5):1682-6. PubMed ID: 17437782
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor size on the long-term survival of patients with early stage renal cell cancer.
Kuczyk M; Wegener G; Merseburger AS; Anastasiadis A; Machtens S; Zumbrägel A; Hartmann JT; Bokemeyer C; Jonas U; Stenzl A
World J Urol; 2005 Feb; 23(1):50-4. PubMed ID: 15729558
[TBL] [Abstract][Full Text] [Related]
6. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent.
Gilbert SM; Murphy AM; Katz AE; Goluboff ET; Sawczuk IS; Olsson CA; Benson MC; McKiernan JM
Urology; 2006 Aug; 68(2):287-91. PubMed ID: 16904438
[TBL] [Abstract][Full Text] [Related]
7. Reassessment of the 1997 TNM classification system for renal cell carcinoma.
Elmore JM; Kadesky KT; Koeneman KS; Sagalowsky AI
Cancer; 2003 Dec; 98(11):2329-34. PubMed ID: 14635066
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma.
Steiner T; Knels R; Schubert J
Eur Urol; 2004 Sep; 46(3):327-30. PubMed ID: 15306102
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?
Brookman-May SD; May M; Wolff I; Zigeuner R; Hutterer GC; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Feciche B; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin Mdel C; Salzano L; Lotrecchiano G; Zastrow S; Wirth M; Sountoulides P; Shariat S; Waidelich R; Stief C; Gunia S; ;
Eur Urol; 2015 May; 67(5):943-51. PubMed ID: 25684695
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience.
Lam JS; Klatte T; Patard JJ; Goel RH; Guillè F; Lobel B; Abbou CC; De La Taille A; Tostain J; Cindolo L; Altieri V; Ficarra V; Artibani W; Prayer-Galetti T; Schips L; Zigeuner R; Pantuck AJ; Figlin RA; Belldegrun AS
Eur Urol; 2007 Jul; 52(1):155-62. PubMed ID: 17316970
[TBL] [Abstract][Full Text] [Related]
11. Influence of tumor size on oncological outcomes of pathological T3aN0M0 renal cell carcinoma treated by radical nephrectomy.
Chen L; Ma X; Li H; Gu L; Li X; Gao Y; Xie Y; Zhang X
PLoS One; 2017; 12(3):e0173953. PubMed ID: 28288191
[TBL] [Abstract][Full Text] [Related]
12. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
Ristau BT; Handorf EA; Cahn DB; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2018 Oct; 124(19):3839-3848. PubMed ID: 30207380
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma.
Shao Y; Xiong S; Sun G; Dou W; Hu X; Yang W; Lia T; Deng S; Wei Q; Zeng H; Li X
Cancer Med; 2020 Feb; 9(3):959-970. PubMed ID: 31840431
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of segmental renal vein invasion on recurrence in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy.
Yoshida T; Ohe C; Tsuzuki T; Sugi M; Kinoshita H; Tsuta K; Matsuda T
Int J Clin Oncol; 2020 Mar; 25(3):464-471. PubMed ID: 31531786
[TBL] [Abstract][Full Text] [Related]
15. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
[TBL] [Abstract][Full Text] [Related]
16. Association of Extrarenal Invasion Patterns and Tumor Size with the Differences in Survival Outcomes of T3a Renal Cell Carcinoma: A Proposal Modified T3a Stage System is Needed.
Wu X; Wang Q; Wang Z; Zhao X; Xu X
Int J Gen Med; 2022; 15():367-378. PubMed ID: 35027844
[TBL] [Abstract][Full Text] [Related]
17. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
[TBL] [Abstract][Full Text] [Related]
18. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
Lau WK; Cheville JC; Blute ML; Weaver AL; Zincke H
Urology; 2002 Apr; 59(4):532-7. PubMed ID: 11927308
[TBL] [Abstract][Full Text] [Related]
19. [Reassessment of T classification system cutoff value for renal cell carcinoma].
Obara T; Matsuura S; Inoue T; Kumazawa T; Abe A; Horikawa Y; Togashi H; Yuasa T; Tsuchiya N; Satoh S; Sato K; Habuchi T
Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):671-6. PubMed ID: 17682445
[TBL] [Abstract][Full Text] [Related]
20. Tumor Size Significantly Affects Prognosis in Pathological T3a Renal Cell Carcinoma.
Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Hung SC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2022 Apr; 42(4):2185-2191. PubMed ID: 35347043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
